Grant J, North S, Lanore D
Small Animal Oncology, Rutland House Referrals, St Helens, Merseyside WA9 4HU.
Small Animal Oncology, VRCC, Laindon, Essex SS15 6TP.
J Small Anim Pract. 2016 Jun;57(6):283-90. doi: 10.1111/jsap.12480. Epub 2016 May 2.
To retrospectively evaluate the clinical response and toxicity associated with masitinib mesylate (Masivet®) treatment of macroscopic mast cell tumours in the dog.
Retrospective review of medical records of 39 dogs that had undergone treatment with masitinib for macroscopic mast cell tumours. Patient signalment, tumour location, tumour grade, tumour stage, previous treatments, concurrent medications, dose of masitinib, side effects, response, time to tumour progression, survival time and cause of death were documented. Response was assessed according to RECIST criteria.
Clinical response was observed in 32 (82·1%) dogs receiving masitinib, with 15 dogs (38·5%) exhibiting a complete response and 17 dogs (43·6%) achieving a partial response. The median time to progression was 79 days (range: 14 to 667 days). Adverse effects were seen in 25 dogs (64·1%) with serum alanine aminotransferase elevation (n=9; 23·1%) and vomiting (n=6; 15·4%) being most common. Median survival time following initiation of masitinib was 159 days (range: 14 to 1339).
Masitinib appears to be a well-tolerated and effective drug against macroscopic mast cell tumours.
回顾性评估甲磺酸马西替尼（Masivet®）治疗犬类肉眼可见肥大细胞瘤的临床反应及毒性。
回顾性分析39只接受甲磺酸马西替尼治疗肉眼可见肥大细胞瘤犬的病历。记录了患犬的特征、肿瘤位置、肿瘤分级、肿瘤分期、既往治疗、同时使用的药物、甲磺酸马西替尼剂量、副作用、反应、肿瘤进展时间、生存时间及死亡原因。根据RECIST标准评估反应。
32只（82.1%）接受甲磺酸马西替尼治疗的犬观察到临床反应，其中15只犬（38.5%）完全缓解，17只犬（43.6%）部分缓解。进展的中位时间为79天（范围：14至667天）。25只犬（64.1%）出现不良反应，最常见的是血清丙氨酸氨基转移酶升高（n = 9；23.1%）和呕吐（n = 6；15.4%）。开始使用甲磺酸马西替尼后的中位生存时间为159天（范围：14至1339天）。
甲磺酸马西替尼似乎是一种耐受性良好且有效的抗肉眼可见肥大细胞瘤药物。
Zotero 插件